Skip to Main Content

Mirati Therapeutics said Monday that more than 60% of patients with lung cancer showed confirmed tumor responses when its experimental KRAS-blocking drug was added to Merck’s Keytruda immunotherapy.

While the study results are preliminary and derived from only eight patients, Mirati is hoping that a promising combination therapy in lung cancer will help narrow the competitive gap with its biggest rival, Amgen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment